The PARADIGM‐HF trial showed that treatment with LCZ696 in heart failure patients significantly reduced the rate of deaths and hospitalization from cardiovascular causes compared to ACE inhibitor (McMurray et al., 2014). This evidence concerns the gene ACE and heart failure.